Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.55% 180.00 1,645,367 16:35:06
Bid Price Offer Price High Price Low Price Open Price
178.00 180.00 183.00 179.00 183.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -4.79 -3.55 297
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:28 O 10,000 180.00 GBX

Synairgen (SNG) Latest News

More Synairgen News
Synairgen Investors    Synairgen Takeover Rumours

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
22/10/202023:05SNG001; a potential treatment for Covid 1921,390
22/10/202021:34Synairgen - a potential cure for Covid 19?14,427
20/10/202023:38Bullshit free zone99
19/10/202014:59WatchOoT fer pump&dump merchants93
14/10/202020:19Synairgen - a cure for Asthma?3,257

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:36:40180.0010,00018,000.00O
17:21:07179.2010,00017,920.00O
17:18:42180.0010,00018,000.00O
16:15:45180.005,5529,993.60O
16:15:00186.0050,00093,000.00O
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

DateSubject
22/10/2020
09:20
Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 181p.
Synairgen Plc has a 4 week average price of 145.50p and a 12 week average price of 145.50p.
The 1 year high share price is 259p while the 1 year low share price is currently 5.75p.
There are currently 165,104,676 shares in issue and the average daily traded volume is 4,431,374 shares. The market capitalisation of Synairgen Plc is £297,188,416.80.
16/10/2020
13:07
festario: But it was 51p higher.... just one hour before the placing.Anyway the size of the discount is irrelevant, the share price will ALWAYS find its way daw to the placing price, or sometimes below.When I saw people saying that the share price would surge above 230 on Wednesday night, I couldn't believe the naivety I was reading.
15/10/2020
07:36
dmdmdmdm1: A little confused here, first time.e I have been involved in a placing. I expected the share price to dip to 175 today, then hover there for a while. Therefore i was tempted to instead top up if there any dips below that.However, I now get the feeling the share price may actually rise, and so 175 may be a good opportunity, if that is what existing shareholders are being offered?
14/10/2020
22:09
verger: Those who are wondering why a major hasn’t taken SNG out, maybe they saw the Numis valuation are realised that they were up against forewarned shareholders. Just a thought. Regarding share price movement, a big placing for very good reasons can only be good news. In SNG’s case, very good news.
14/10/2020
20:49
festario: I've taken ages to read the longest RNS I've ever seen.In essence, it's dilution of my shareholding and I always hate that. But, it's an entirely expected one.So, more fool me for not keeping funds aside to take advantage of it. I'm fully committed here and elsewhere.However, in the morning, the price WILL plummet, possibly in a flash, by the full 50p, down to 175pThat will prevent any current holders from selling, buying back, and pocketing the difference.It might only fall to 195p or so, and stabilise there.But... remember, there will be a huge churn of profit taking, on all these 175p shares, for probably months to come.Without any unexpected good news, the share price is effectively mired within a 25% level above 175p.I hope I'm wrong, but I've seen it way too many times.The only things that will significantly shift the share price higher, would be a partner announcement, EUA, or physical sight of orders.
12/10/2020
18:30
rosco230667: Numis bull £50 per shareToday 17:55NumisSynairgen (Buy, TP: 990p) World-class asset to treat SARS-CoV-2Synairgen has developed an inhaled version of interferon-beta (SNG001), that has recently proven highly effective for the treatment of SARS-CoV-2 (COVID-19) in a gold-standard, placebo-controlled Phase 2 study conducted across leading respiratory centres in the UK. The drug is widely known to enhance the innate immune response, which is the body's first line of defense against viruses, and is unique in being delivered directly into the lungs, where respiratory viruses initally take hold. Subject to funding we expect a pivotal trial to start before the end of the year, and if the Phase 2 data is replicated in a larger Phase 3 study, SNG001 would be the most effective treatment for SARS-CoV-2 with future potential to treat various seasonal, endemic, and pandemic threats. We initiate coverage with a Buy rating and 990p price target (6x upside) derived from a base (70%)/bear (30%) scenario analysis, which in our view represents a very compelling risk/reward proposition.Download World-class asset to treat SARS-CoV-2(36 pages)Prospects have been transformed: The ongoing SARS-CoV-2 pandemic has demonstrated the threat posed by respiratory viruses. In a matter of months, capabilities have evolved to be able to test for, track and isolate infected patients to protect the vulnerable, yet numbers of cases, hospitalisations and sadly deaths, are still rising. We expect this capability will be retained, and that a therapeutic market and infrastructure for identifying and treating SARS-CoV-2 (and other respiratory viruses) has been rapidly created, that could be worth $20bn/year, a fraction of the costs of global lockdown.Innately attractive: The innate immune response is known to weaken with age and illness (Source: WHO). The elderly and those with underlying conditions are the most vulnerable to SARS-CoV-2. SNG001 has been shown to activate, enhance and extend the innate, antiviral defense as measured using biomarkers in these patients. Synairgen's drug has previously been shown to be effective against SARS-1 and MERS, and based on Phase 2 data appears more effective than Gilead's Remdesivir. Insights from industry players, clinicians and KOLs support our views.Compelling risk/reward: We detail the risks facing Synairgen throughout this note, but given the strong data in Phase 2, we place the chance of Phase 3 success at 70%, slightly above the industry average. The question then becomes what value can be placed on a drug that treats the vulnerable and could enable a return to the old normal? Our Bull case extends to £50/sh based on the valuations of Moderna/BioNTech with a need for SNG001 whether or not the vaccines prove successful.
09/10/2020
10:13
stampylong trader: Join the dots. It's sad to see the people on LSE all scrabbling around and asking why is the government leaving us behind? Why are we being ignored? We have this great therapeutic and no one wants to know about it? Let us all write to all our MPs, let us write to the journalists, the CEO's of airlines, cinemas, and hotels etc. SNG is our silver bullet. This isn't about COVID - this is about shaping the world. COVID is just the catalyst towards that. I challenge all SNG holders with 1000 shares or more to look into "Build Back Better" (BBB) which is the agenda for the post COVID world. I challenge every holder to spend 20 minutes looking up BBB and The Global Reset talked about by Klaus Schwab. BBB did not come about by accident by Boris or Biden - it is an agenda to reshape the world. I do not think SNG fits into BBB's plans. Vaccines do, which is why government appears to be ignoring SNG and other therapeutics. They are pursuing the stewardship of the World Economic Forum. If you are bull on SNG - SNG will have to do it without the help of government.
30/9/2020
16:27
njb67: The NHS have plenty of money for Covid medicines and the government would find additional if this became an issue. Can only guess on why the share price has fallen - uncertainty about when this product will get to market, will it be too late if a vaccine gets here first? - uncertainty about how much the company is worth? with or without a vaccine or cure for Covid? - I suspect that there are a lot of folk sitting on big gains having bought in pre-results. Only natural for some of these to cash in some or all of these gains (4xSP overnight?). Healthy profit taking or fear of losing profits - human psychology - if the share price is falling and you are sitting on gains, then there is a natural urge to sell So a mix of it being difficult to know how much the company is worth and (ir)rational responses to share price movements. Edit: just saw realcapital city post - it could be enemy action too...
28/9/2020
16:55
festario: I think a very clever game is being played here, by those who realise that when the interim results are announced, the share price is highly likely to tank.SNG doesn't make a net profit, and it's losses will be apparent due to its R&D costs.The market always drops a share price when a company with a high market capitalisation announces a widening loss.It will recover later in the day, but it will look a bit sick in early trading.Those who realise that, but are bullish longer term, have cleverly dumped a load of shares around 180p to 200p.... and will be able to buy them back around 120p on the morning of the results.Only a VERY bullish forward looking statement can possibly avoid this situation.
25/9/2020
16:11
master rsi: MMs happy to play with the spread so as soon as the share price goes to high of the day 180p 0ffer, with 6p spread, one goes lower on the offer 178p but still above the price earlier for buying 177p. so some investors think the share price goes down but is not and sell and they MMs are filling up their book again. 174 v 180p now 174 v 178p 2 at bid 1 at offer
08/9/2020
07:08
nortic 007: Synairgen plc Positive interim analysis of SNG001 in COPDSource: UK Regulatory (RNS & others)TIDMSNGRNS Number : 2832YSynairgen plc08 September 2020Press releaseSynairgen plc('Synairgen' or the 'Company')Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients - SNG001 well tolerated in this older population with a significant co-morbidity (COPD) - Strong interferon driven antiviral biomarker response - Data support future progression of SNG001 for exacerbating COPD patients - Positive data supportive of SNG001 COVID-19 programme Southampton, UK - 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection.Key findings -- Safety SNG001 was well tolerated during the treatment period in a study population that was elderly (mean age 66 years) and suffering from reduced respiratory function, as measured by forced expiratory volume in one second (FEV1) (59% of predicted value). The percentage of on-treatment adverse events was similar in the placebo and SNG001 treatment groups (48.1% versus 45.6%, respectively), with treatment-related adverse events being more frequent in the placebo group (25%) compared to the SNG001 group (15.8%). This safety data add to the safety database for SNG001, supporting Synairgen's interactions with regulatory agencies in respect of COVID-19, where older age and poor lung function are risk factors. -- Antiviral activity Over the treatment period, lung antiviral responses to viral infection were significantly enhanced in patients receiving SNG001 compared to those on placebo, as assessed by measuring increases in the gene expression of interferon beta-dependent antiviral biomarkers MX1 (p=
Synairgen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SNG
Synairgen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 22:12:56